Abstract P010 – Table 1. Analysis of nine samples
| Tenofovir disproxil fumarate | Emtricitabine | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug no. | Drug name | Manufacturer | Lot no. | Expiration date | Supplier source | Measured amount in mg | % of label claim (300 mg) | Measured amount in mg | % of label claim (200 mg) |
| 0 | Truvada | Gilead | 5595307D | Nov‐19 | Imperial Healthcare NHS Trust | 300.1 | 100.0 | 201.2 | 100.6 |
| 1 |
Emtricitabine/ tenofovir disoproxil |
Mylan | 1091973 | not available | IMPACT trial | 299.2 | 99.7 | 198.3 | 99.2 |
| 2 | RICOVIR‐EM | Mylan | 3067417 | Apr‐20 | Dynamix International | 307.4 | 102.5 | 201.6 | 100.8 |
| 3 | TENVIR‐RM | Cipla | GG80516 | Feb‐20 | In House Pharmacy | 314.8 | 104.9 | 208.4 | 104.2 |
| 4 | TENOF‐EM | Hetero Healthcare | 31171625 | Apr‐20 | Dynamix International | 306.4 | 102.1 | 205.2 | 102.6 |
| 5 | TENOF‐EM | Hetero Healthcare | 31171625 | Apr‐20 | Green Cross Pharmacy | 313.2 | 104.4 | 207.2 | 103.6 |
| 6 | TENVIR‐EM | Cipla | GG80516 | Feb‐20 | Dynamix International | 312.0 | 104.0 | 208.7 | 104.4 |
| 7 | TAVIN‐EM | Emcure | E16HX18001 | Dec‐20 | United Pharmacy | 283.0 | 94.3 | 194.7 | 97.3 |
| 8 | TENVIR‐EM | Cipla | GG80114 | Dec‐19 | United Pharmacy | 307.5 | 102.5 | 203.5 | 101.8 |